Goodwin Advises Mission BioCapital on Securing Eligibility for $44.5 Million Non-Dilutive Funding Through AMED Program

Professionals

Goodwin’s Life Sciences and Private Equity teams advised Mission BioCapital (MBC) on its successful application to participate in the Japan Agency for Medical Research and Development (AMED) Drug Discovery Venture Ecosystem Enhancement Project. The program enables certified venture capital firms and AMED-approved portfolio companies to access significant non-dilutive funding for therapeutic development, including up to approximately $44.5 million per program through a 2:1 government matching mechanism tied to qualifying venture capital investments. The initiative is designed to strengthen Japan’s drug discovery ecosystem and accelerate the development of innovative therapies. MBC was supported in its application by its affiliate, BioLabs.

AMED’s highly selective program is currently offered through biannual application cycles. In the latest cycle, MBC was one of only five venture capital firms selected from a pool of 13 applicants following an extensive review of application materials and interviews conducted by AMED.

MBC is a leading life sciences venture capital firm and startup development platform that invests in and supports innovative biotechnology companies. Through its investment activities and broader life sciences network, MBC helps entrepreneurs translate scientific discoveries into venture-backed companies and advance promising technologies toward commercialization, making it well positioned to identify and support high-potential therapeutic opportunities under the AMED program.

BioLabs are the premier co-working spaces for life sciences startups, unique places where startups can test, develop, and grow their game-changing ideas. BioLabs’ goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bioinnovators to grow quickly, while maximizing capital efficiency. BioLabs operates an international network of shared lab and office facilities, including in Tokyo.

The Goodwin team was led by James T. Barrett and Miho Kaneko. Goodwin’s Life Sciences and Private Equity groups work with investors, entrepreneurs, and innovative life sciences companies across the full lifecycle of their businesses, combining deep industry knowledge with global capabilities to help clients navigate complex investment, financing, and growth opportunities.

Goodwin Advises Mission BioCapital on Securing Eligibility for $44.5 Million Non-Dilutive Funding Through AMED Program

Related Content

Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars

FDA Approves Ultragenyx’s GENGLYCOS™ Gene Therapy for GSDIa

FDA approves Regeneron’s PASATRU™ (garetosmab-grts) for Fibrodysplasia Ossificans Progressiva

FDA Addresses FAQs on Developing Potential Cellular and Gene Therapy Products

Takeda Files BPCIA Suit Against Polpharma Biologics For Vedolizumab Biosimilar

Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK

Biocon Launches Aflibercept Biosimilar in the United States

$46 Million Veloxis Settlement Yields Record Sunshine Penalty and Insights Into DOJ’s Cross-Agency Data Use

Goodwin Pharma Services Symposium

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Strengthens Life Sciences and Public M&A Platform With Partner Ro Park

Goodwin Advises Moderna in $3 Billion 0.00% Convertible Senior Notes Offering and Capped Call

Goodwin Advises Merida Biosciences in up to $2.875 Billion Acquisition by Eli Lilly

Goodwin Advises Aureka Biotechnologies on Intellectual Property Aspects for $100 Million Series B

Goodwin Advises Amylyx Pharmaceuticals on $575 Million Public Offering

Goodwin Advises AbCellera Biologics on $200 Million Public Offering

Life Sciences

Private Equity